Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira®.

@article{Lee2019DemonstrationOF,
  title={Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira®.},
  author={J. J. Lee and Junmo Yang and C. Lee and Youngjin Moon and S. Ahn and Jiyoon Yang},
  journal={Biologicals : journal of the International Association of Biological Standardization},
  year={2019},
  volume={58},
  pages={
          7-15
        }
}
  • J. J. Lee, Junmo Yang, +3 authors Jiyoon Yang
  • Published 2019
  • Chemistry, Medicine
  • Biologicals : journal of the International Association of Biological Standardization
  • A biosimilar is a biological medicinal product that is highly similar to an authorized biological product in terms of quality, biological activity, safety and efficacy. SB5 was developed by Samsung Bioepis as a biosimilar referencing adalimumab, and was authorized by the European Commission (EC) in August 2017 (Imraldi®). Extensive characterization studies were performed to demonstrate functional similarity of SB5 to reference adalimumab (Humira®, AbbVie Inc. and AbbVie Deutschland GmbH & Co… CONTINUE READING
    4 Citations

    References

    SHOWING 1-10 OF 22 REFERENCES
    Considerations in the early development of biosimilar products.
    • 24
    • PDF
    Fc glycans of therapeutic antibodies as critical quality attributes
    • 190
    • PDF